Please wait while the formulary information is being retrieved.
FERAHEME (FERUMOXYTOL)
- Anemia in chronic kidney disease
- Iron deficiency anemia
510 mg/17 mL (30 mg/mL) intravenous solution
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- Hemosiderosis
Contraindicated
- Chronic iron overload
Severe
Moderate
- Hypotension
- Magnetic resonance imaging
FERAHEME (FERUMOXYTOL)
- Anemia in chronic kidney disease
- Iron deficiency anemia
- Hypotension
- Constipation
- Diarrhea
- Dizziness
- Fatigue
- Headache disorder
- Nausea
- Peripheral edema
More Frequent
Severe
Less Severe
- Chest pain
- Hypersensitivity drug reaction
- Acute abdominal pain
- Back pain
- Cough
- Ecchymosis
- Fever
- Hypertension
- Injection site sequelae
- Muscle spasm
- Pruritus of skin
- Skin rash
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Cardiac arrest
- Chronic heart failure
- Cyanosis
- Dyspnea
- Hemosiderosis
- Myocardial ischemia
- Severe hypotension
- Syncope
- Unconsciousness
Less Severe
- Tachycardia
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ferumoxytol_Ferric carboxymaltose
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Ferumoxytol
- Severity Level:
2
- Additional Notes: Insuff human data avail; consider maternal tx benefit vs pot fetal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Ferumoxytol
None
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Ferumoxytol
General-Elderly with pre-existing serious or multiple co-morbidities and experience a hypersensitivity reaction are at risk of severe outcome (i.e., cardiac/cardiorespiratory arrest, severe hypotension, syncope).
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | Y | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Rarely, some people using this medication have had a serious allergic reaction, even if they did not have a reaction in the past. You will need to stay in a clinic or hospital during and for at least 30 minutes after your injection so your doctor can monitor you closely and check your blood pressure and pulse. Get medical help right away if you develop symptoms such as rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, fainting, trouble breathing.
| Anemia in chronic kidney disease | |
| D63.1 | Anemia in chronic kidney disease |
| N18.4 | Chronic kidney disease, stage 4 (severe) |
| N18.5 | Chronic kidney disease, stage 5 |
| N18.6 | End stage renal disease |
| Z99.2 | Dependence on renal dialysis |
| Iron deficiency anemia | |
| D50 | Iron deficiency anemia |
| D50.0 | Iron deficiency anemia secondary to blood loss (chronic) |
| D50.8 | Other iron deficiency anemias |
| D50.9 | Iron deficiency anemia, unspecified |
| 0-9 | A-Z |
|---|---|
| D50 | Iron deficiency anemia |
| D50.0 | Iron deficiency anemia secondary to blood loss (chronic) |
| D50.8 | Other iron deficiency anemias |
| D50.9 | Iron deficiency anemia, unspecified |
| D63.1 | Anemia in chronic kidney disease |
| N18.4 | Chronic kidney disease, stage 4 (severe) |
| N18.5 | Chronic kidney disease, stage 5 |
| N18.6 | End stage renal disease |
| Z99.2 | Dependence on renal dialysis |
Formulary Reference Tool